\u00d6ruggarapart\u00fdi\u00f0 \u00ed Z\u00fcrich<\/a>, stofnun sem pr\u00f3far \u00f6ryggi f\u00edkniefna \u00e1 g\u00f6tum \u00fati, s\u00fdni sem selt er sem 3-MMC (3-met\u00fdlmetkat\u00edn\u00f3n)<\/b> innih\u00e9lt \u00ed raun anna\u00f0 efni: 2-MMC (2-met\u00fdlmetkat\u00edn\u00f3n)<\/b>\u00de\u00f3 a\u00f0 n\u00f6fnin hlj\u00f3mi n\u00e6stum eins, \u00fe\u00e1 eru \u00feau ekki \u00fea\u00f0 sama - og \u00e1hrifin \u00e1 l\u00edkamann g\u00e6tu veri\u00f0 mj\u00f6g mismunandi.<\/p>\n\u00deessi uppg\u00f6tvun var ger\u00f0 vi\u00f0 nafnlausa lyfjaeftirlits\u00fej\u00f3nustu \u00ed Z\u00fcrich, sem gerir f\u00f3lki kleift a\u00f0 pr\u00f3fa efni \u00e1\u00f0ur en \u00fea\u00f0 notar \u00feau. \u00de\u00f6kk s\u00e9 \u00feessari \u00fej\u00f3nustu var rangmerkingin uppg\u00f6tvu\u00f0 \u00e1\u00f0ur en fleiri voru settir \u00ed h\u00e6ttu. En \u00feetta vekur miklar \u00e1hyggjur: <\/p>\n
Getur\u00f0u virkilega treyst \u00fev\u00ed sem \u00fe\u00fa kaupir \u00e1 g\u00f6tunni?<\/b><\/p>\nHver er munurinn \u00e1 3-MMC og 2-MMC?<\/h2>\n
\u00c1 yfirbor\u00f0inu eru \u00feessi tilb\u00fanu lyf svipu\u00f0 a\u00f0 uppbyggingu \u2014 \u00feau eru b\u00e6\u00f0i hluti af kat\u00f3nfj\u00f6lskyldan<\/b>, sem inniheldur efni sem oft eru borin saman vi\u00f0 amfetam\u00edn. En \u00fe\u00f3tt \u00feau l\u00edti \u00fat eins \u00fe\u00fd\u00f0ir \u00fea\u00f0 ekki a\u00f0 \u00feau heg\u00f0i s\u00e9r eins.<\/p>\n3-MMC (3-met\u00fdlmetkat\u00edn\u00f3n)<\/h3>\n
3-MMC hefur veri\u00f0 \u00feekkt me\u00f0al af\u00fereyingarneytenda sem \u00f6rvandi efni sem veitir vell\u00ed\u00f0an, aukna orku og f\u00e9lagslyndi. En \u00fea\u00f0 er enginn engill. \u00dea\u00f0 getur samt valdi\u00f0 aukaverkunum eins og kv\u00ed\u00f0a, svefnleysi og jafnvel hjartavandam\u00e1lum \u00ed st\u00f3rum sk\u00f6mmtum. \u00dea\u00f0 var\u00f0 vins\u00e6lt sem sta\u00f0gengill fyrir mefedr\u00f3n eftir a\u00f0 \u00fea\u00f0 var banna\u00f0 \u00ed m\u00f6rgum l\u00f6ndum.<\/p>\n
2-MMC (2-met\u00fdlmetkat\u00edn\u00f3n)<\/h3>\n
2-MMC er mun minna rannsaka\u00f0. \u00dear liggur h\u00e6ttan \u00ed raun og veru. Vi\u00f0 vitum ekki a\u00f0eins mj\u00f6g l\u00edti\u00f0 um skammt\u00edma\u00e1hrif \u00feess, heldur enn minna um langt\u00edmaaflei\u00f0ingar \u00feess \u00e1 heila og l\u00edkama.<\/p>\n
Me\u00f0 \u00f6\u00f0rum or\u00f0um, a\u00f0 taka 2-MMC \u00feegar \u00fe\u00fa heldur a\u00f0 \u00fea\u00f0 s\u00e9 3-MMC g\u00e6ti veri\u00f0 eins og a\u00f0 skipta \u00fat s\u00edtr\u00f3nusafa fyrir bleikiefni. Vir\u00f0ist dramat\u00edskt? Kannski. En \u00feegar \u00fe\u00fa setur \u00f3\u00feekkt efni \u00ed l\u00edkamann, \u00fe\u00e1 ertu a\u00f0 fj\u00e1rh\u00e6ttuspila.<\/p>\n
Af hverju er \u00feetta h\u00e6ttulegt?<\/h2>\n
St\u00e6rsta h\u00e6ttan stafar af \u00f3v\u00e6ntu e\u00f0li efnisins. Ef einhver telur sig vera a\u00f0 taka 3-MMC g\u00e6ti hann vali\u00f0 skammt \u00fat fr\u00e1 \u00feeirri v\u00e6ntingu. 2-MMC g\u00e6ti veri\u00f0 \u00f6flugra, eitrara e\u00f0a haft \u00f6nnur samskipti vi\u00f0 \u00f6nnur efni.<\/b>\u00dea\u00f0 eykur verulega h\u00e6ttuna \u00e1:<\/p>\n\n- Ofsk\u00f6mmtun<\/b><\/li>\n
- Neikv\u00e6\u00f0ar aukaverkanir<\/b> eins og kv\u00ed\u00f0ak\u00f6st, \u00f3gle\u00f0i e\u00f0a flog<\/li>\n
- \u00d3fyrirsj\u00e1anleg samskipti<\/b> me\u00f0 \u00e1fengi e\u00f0a \u00f6\u00f0rum f\u00edkniefnum<\/li>\n
- Langt\u00edma ge\u00f0heilbrig\u00f0isvandam\u00e1l<\/b><\/li>\n<\/ul>\n
Vi\u00f0 skulum horfast \u00ed augu vi\u00f0 \u00fea\u00f0: \u00feegar kemur a\u00f0 f\u00edkniefnum \u00e1 g\u00f6tunni ertu \u00feegar farinn a\u00f0 ganga inn \u00e1 h\u00e6ttulegt sl\u00f3\u00f0. En \u00feegar efni\u00f0 er ekki einu sinni \u00fea\u00f0 sem \u00fea\u00f0 lofar a\u00f0 vera? \u00de\u00e1 ertu a\u00f0 fara inn \u00e1 h\u00e6ttulegt sl\u00f3\u00f0.<\/p>\n
Hvernig var mist\u00f6kin uppg\u00f6tvu\u00f0?<\/h2>\n
Sem betur fer var \u00feessi ruglingur \u00ed merkimi\u00f0anum uppg\u00f6tva\u00f0ur \u00fe\u00f6kk s\u00e9 pr\u00f3funar\u00fej\u00f3nustu Saferparty.ch \u00ed Z\u00fcrich. \u00deeir bj\u00f3\u00f0a upp \u00e1 nafnlausar pr\u00f3fanir \u00e1 af\u00fereyingarf\u00edkniefnum \u00e1n ford\u00f3ma. \u00deetta er ver\u00f0m\u00e6tt t\u00e6ki til a\u00f0 draga \u00far ska\u00f0a - \u00fea\u00f0 hj\u00e1lpar f\u00f3lki a\u00f0 taka uppl\u00fdstar \u00e1kvar\u00f0anir bygg\u00f0ar \u00e1 sta\u00f0reyndum, ekki \u00e1giskunum.<\/p>\n
Umr\u00e6dda pillan var hv\u00edtt duft sem selt var \u00e1 g\u00f6tunni og marka\u00f0ssett sem 3-MMC. Ranns\u00f3knarstofupr\u00f3f s\u00fdndu hi\u00f0 gagnst\u00e6\u00f0a og greindu \u00ed sta\u00f0inn 2-MMC. Og m\u00e1li\u00f0 er: s\u00e1 sem keypti hana haf\u00f0i l\u00edklega ekki hugmynd um \u00fea\u00f0.<\/p>\n
Hvernig getur\u00f0u veri\u00f0 \u00f6ruggur?<\/h2>\n
\u00dea\u00f0 er alltaf best a\u00f0 for\u00f0ast tilb\u00fain f\u00edkniefni alveg, s\u00e9rstaklega \u00feau sem eru fengin \u00e1 svartamarka\u00f0i. En ef \u00fe\u00fa e\u00f0a einhver sem \u00fe\u00fa \u00feekkir \u00e1kve\u00f0ur a\u00f0 nota efni, \u00fe\u00e1 er ska\u00f0aminnkun lykilatri\u00f0i.<\/p>\n
H\u00e9r eru nokkur r\u00e1\u00f0 til a\u00f0 draga \u00far \u00e1h\u00e6ttunni:<\/p>\n
\n- Noti\u00f0 lyfjaeftirlits\u00fej\u00f3nustu<\/b> \u00feegar m\u00f6gulegt er. Sta\u00f0ir eins og Z\u00fcrich bj\u00f3\u00f0a upp \u00e1 tr\u00fana\u00f0arpr\u00f3f.<\/li>\n
- Byrja\u00f0u h\u00e6gt<\/b>Ef \u00fe\u00fa ert \u00f3viss um hva\u00f0 \u00fe\u00fa ert a\u00f0 taka skaltu byrja \u00e1 litlum skammti.<\/li>\n
- Ekki blanda efnum saman<\/b>A\u00f0 blanda f\u00edkniefnum saman \u2013 jafnvel vi\u00f0 \u00e1fengi \u2013 getur skapa\u00f0 h\u00e6ttulegar milliverkanir.<\/li>\n
- Noti\u00f0 aldrei eitt s\u00e9r<\/b>Gakktu \u00far skugga um a\u00f0 einhver s\u00e9 n\u00e1l\u00e6gt sem getur hj\u00e1lpa\u00f0 ef sl\u00e6m vi\u00f0br\u00f6g\u00f0 koma upp.<\/li>\n
- G\u00e6ttu a\u00f0 vinum \u00fe\u00ednum<\/b>Hafi\u00f0 augun opin hvert fyrir \u00f6\u00f0ru. \u00deegar eitthva\u00f0 vir\u00f0ist ekki \u00ed lagi, l\u00e1ti\u00f0 vita.<\/li>\n<\/ul>\n
Af hverju \u00fe\u00fa \u00e6ttir a\u00f0 hafa \u00e1hyggjur - jafnvel \u00fe\u00f3tt \u00fe\u00fa notir \u00fea\u00f0 ekki<\/h2>\n
\u00de\u00fa g\u00e6tir veri\u00f0 a\u00f0 hugsa: \u201e\u00c9g nota ekki f\u00edkniefni, af hverju \u00e6tti \u00feetta a\u00f0 hafa \u00e1hrif \u00e1 mig?\u201c Sannleikurinn er s\u00e1 a\u00f0 \u00f6ryggi f\u00edkniefna er l\u00fd\u00f0heilsum\u00e1l. Og l\u00fd\u00f0heilsa hefur \u00e1hrif \u00e1 okkur \u00f6ll.<\/p>\n
Kannski er unglingur heima hj\u00e1 \u00fe\u00e9r. Kannski vinnuf\u00e9lagi \u00ed part\u00fdi. Kannski vinur sem \u00e1 \u00ed erfi\u00f0leikum. \u00dev\u00ed fleiri sem skilja \u00feessar h\u00e6ttur, \u00fev\u00ed meira getum vi\u00f0 stutt hvert anna\u00f0 vi\u00f0 a\u00f0 taka \u00f6ruggari \u00e1kvar\u00f0anir.<\/p>\n
Hugsa\u00f0u um \u00feetta svona: \u00feekking er eins og \u00f6ryggisbelti. \u00de\u00fa lendir kannski aldrei \u00ed \u00e1rekstri, en ef \u00fe\u00fa gerir \u00fea\u00f0 - \u00fe\u00e1 munt \u00fe\u00fa vera \u00e1n\u00e6g\u00f0ur me\u00f0 a\u00f0 hafa spennt belti\u00f0.<\/p>\n
Lokaor\u00f0: \u00deekking getur bjarga\u00f0 mannsl\u00edfum<\/h2>\n
\u00dea\u00f0 getur veri\u00f0 \u00f3gnvekjandi a\u00f0 komast a\u00f0 \u00fev\u00ed a\u00f0 heimur f\u00edkniefna er ruglingslegri \u2013 og h\u00e6ttulegri \u2013 en hann vir\u00f0ist. En \u00fea\u00f0 er betra a\u00f0 horfast \u00ed augu vi\u00f0 \u00feennan veruleika heldur en a\u00f0 \u00feykjast eins og hann s\u00e9 ekki til. <\/p>\n
Mundu, 2-MMC er ekki 3-MMC<\/b>\u00deessi litli munur \u00e1 nafni getur leitt til mikilla breytinga \u00e1 \u00fev\u00ed hvernig l\u00edkami \u00feinn bregst vi\u00f0. Ef \u00fe\u00fa, e\u00f0a einhver sem \u00fe\u00e9r \u00feykir v\u00e6nt um, ert a\u00f0 vafra um \u00feennan heim, vertu viss um a\u00f0 gera \u00fea\u00f0 me\u00f0 eins mikilli \u00feekkingu og var\u00fa\u00f0 og m\u00f6gulegt er.<\/p>\n
Vertu \u00f6ruggur, vertu uppl\u00fdstur og vertu aldrei hr\u00e6ddur vi\u00f0 a\u00f0 spyrja spurninga.<\/b> \u00dea\u00f0 g\u00e6ti r\u00e9tt bjarga\u00f0 mannsl\u00edfi.<\/p>\nHvar \u00e1 a\u00f0 f\u00e1 hj\u00e1lp<\/h3>\n
Ef \u00fe\u00fa ert \u00ed Z\u00fcrich e\u00f0a n\u00e1grenni og \u00fearft frekari uppl\u00fdsingar e\u00f0a vilt l\u00e1ta pr\u00f3fa \u00feig fyrir f\u00edkniefnum, far\u00f0u \u00fe\u00e1 \u00e1 Saferparty.ch<\/a> fyrir \u00farr\u00e6\u00f0i, stu\u00f0ning og lyfjaeftirlits\u00fej\u00f3nustu \u00feeirra. \u00deau eru h\u00e9r til a\u00f0 hj\u00e1lpa - ekki til a\u00f0 d\u00e6ma.<\/p>\nVi\u00f0 skulum dreifa \u00feessum skilabo\u00f0um og hj\u00e1lpa til vi\u00f0 a\u00f0 taka uppl\u00fdstar \u00e1kvar\u00f0anir a\u00f0 reglum, ekki undantekningum. Eru einhverjar spurningar e\u00f0a hugmyndir til a\u00f0 deila? Skrifi\u00f0 \u00fe\u00e6r \u00ed athugasemdunum h\u00e9r a\u00f0 ne\u00f0an. Vi\u00f0 skulum halda samtalinu gangandi!<\/p>\n
Leitaror\u00f0:<\/h2>\n
2-MMC, 3-MMC, vi\u00f0v\u00f6run um lyfjame\u00f0fer\u00f0 \u00ed Z\u00fcrich, ruglingur lyfja, tilb\u00fain kat\u00edn\u00f3n, af\u00fereyingarlyf, \u00f6ryggi lyfja, ska\u00f0aminnkun, Saferparty.ch, lyfjaeftirlit, rangmerkt lyf, vi\u00f0v\u00f6run um v\u00edmuefnaneyslu, vi\u00f0varanir um lyfjame\u00f0fer\u00f0 \u00ed Sviss<\/p>","protected":false},"excerpt":{"rendered":"
https:\/\/researchchemworld.com\/output1-png-9\/ H\u00e6ttuleg lyfjablanda \u00ed Z\u00fcrich: 2-MMC selt sem 3-MMC Hva\u00f0 ef eitthva\u00f0 sem \u00fe\u00fa h\u00e9lst a\u00f0 v\u00e6ri eitthva\u00f0 reyndist vera \u00ed raun og veru<\/p>","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-26193","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/researchchemworld.com\/is\/wp-json\/wp\/v2\/posts\/26193","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/researchchemworld.com\/is\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/researchchemworld.com\/is\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/researchchemworld.com\/is\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/researchchemworld.com\/is\/wp-json\/wp\/v2\/comments?post=26193"}],"version-history":[{"count":1,"href":"https:\/\/researchchemworld.com\/is\/wp-json\/wp\/v2\/posts\/26193\/revisions"}],"predecessor-version":[{"id":27538,"href":"https:\/\/researchchemworld.com\/is\/wp-json\/wp\/v2\/posts\/26193\/revisions\/27538"}],"wp:attachment":[{"href":"https:\/\/researchchemworld.com\/is\/wp-json\/wp\/v2\/media?parent=26193"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/researchchemworld.com\/is\/wp-json\/wp\/v2\/categories?post=26193"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/researchchemworld.com\/is\/wp-json\/wp\/v2\/tags?post=26193"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}